Investigational agent in development for treatment or prevention of H5N1 Bird Flu
Phase 1 dosing completed in healthy volunteers
Potent inhibition of drug-resistant and bird flu viruses in vitro
In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs
Phase 2 study expected to begin in H1 2025
Traws Pharma is expanding its influenza program to address the potential threat of bird flu
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.